Fluvastatin Sodium Tablet, Film Coated, Extended Release
Product Images NDC 0527-2580

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Fluvastatin Sodium (NDC 0527-2580). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lannett Company, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1. Primary Endpoint – Recurrent Cardiac Events (cardiac Death, Nonfatal Mi Or Revascularization Procedure) (itt Population) (Figure 1)

Figure 1. Primary Endpoint – Recurrent Cardiac Events (cardiac Death, Nonfatal Mi Or Revascularization Procedure) (itt Population) (Figure 1)
FDA Label Image

Figure 2. Fluvastatin Capsules Intervention Prevention Study (Primary and Secondary Endpoints)

Figure 2. Fluvastatin Capsules Intervention Prevention Study (Primary and Secondary Endpoints)
The text describes the results of a study comparing the effectiveness of Fluvastatin with a Placebo in reducing cardiac events, such as cardiac deaths, non-fatal MI, and revascularization. The study showed a risk reduction in primary endpoints, and secondary endpoints such as revascularization, with a higher incidence observed in placebo group patients. The study excluded revascularization of the target lesion within the first 6 months of the initial procedure.*
FDA Label Image

Figure 3 Change In Minimum Lumen Diameter (mm) (Figure 3)

Figure 3 Change In Minimum Lumen Diameter (mm) (Figure 3)
FDA Label Image

Figure 4 Change In % Diameter Stenosis (Figure 4)

Figure 4 Change In % Diameter Stenosis (Figure 4)
FDA Label Image

Commercial Label Design (Fluvastatin Label Sciecure)

Commercial Label Design (Fluvastatin Label Sciecure)
Each tablet contains 80 mg of fluvastatin sodium, a USP equivalent. The usual dosage information can be found in the package insert, and the tablets should be stored at a controlled room temperature, with excursions permitted to a range between 15-30°C. The medication should be protected from light and dispensed in a tight container. This medication is an extended-release tablet, distributed by Lannett Company, forRx-only use, and its active ingredient is from Beiing Sciecure Pharmaceutical Co. Ltd. The product's NDC number is 0527-2580-32 with 30 tablets in a package. It is important to keep this and all drugs away from children.*
FDA Label Image

Fluvastatin Label

Fluvastatin Label
This is a description of Fluvastatin Sodium extended-release tablets, with a strength of 1080 mg. The recommended storage temperature is 25°C with excursions to 15.30°C. It is advised to keep the tablets in a tight container away from light, and out of reach of children. The manufacturer is Beijing Sciecure Pharmaceutical Co. Ltd and the product is distributed by Lannett Company, Inc. with an NDC of 0527-2580-37. The usual dosage is mentioned in the package insert. This product is only available with a prescription.*
FDA Label Image

Fluvastatin Sodium Structural Formula (Fluvastatin Sodium Structure2)

Fluvastatin Sodium Structural Formula (Fluvastatin Sodium Structure2)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.